Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye scans could spot deadly heart disease before symptoms appear

NCT ID NCT07690436

Not yet recruiting Diagnosis Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study explores whether specialized eye imaging can identify people with a rare heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). Researchers will use machine learning to analyze eye scans from 500 adults—some with ATTR-CM and others with heart failure but not ATTR-CM. The goal is to see if the eyes can serve as a window to the heart, offering a non-invasive screening method.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple, non-invasive eye test to screen for a serious heart condition, potentially catching it earlier.
What could go wrong
This is an early pilot study. The machine learning model may not be accurate enough, and eye imaging might not reliably distinguish ATTR-CM from other heart conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure wild type ATTR amyloidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRANSTHYRETIN AMYLOID CARDIOMYOPATHY

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    Palo Alto, California, 94305, United States

  • Research Site

    Chicago, Illinois, 60611, United States

  • Research Site

    Boston, Massachusetts, 02114, United States

  • Research Site

    Portland, Oregon, 97239-3098, United States

  • Research Site

    Germantown, Tennessee, 38138, United States

  • Research Site

    Essen, 45147, Germany

  • Research Site

    Würzburg, 97078, Germany

  • Research Site

    Guimarães, 4835-044, Portugal

  • Research Site

    L'Hospitalet de Llobregat, 08907, Spain

  • Research Site

    Palma de Mallorca, 07198, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.